logo
CATalyst Council Unveils 2025 Feline Market Insights Report Volume II: $12 Billion Market Reveals $20 Billion Opportunity to Close the Feline Care Gap

CATalyst Council Unveils 2025 Feline Market Insights Report Volume II: $12 Billion Market Reveals $20 Billion Opportunity to Close the Feline Care Gap

Business Wire7 hours ago

ANNAPOLIS, Md.--(BUSINESS WIRE)--The CATalyst Council, the veterinary industry's leading authority on the feline market, released Volume II of its 2025 Feline Market Insights Report. This data-driven resource offers an in-depth examination of U.S. feline healthcare dynamics, owner behaviors, and veterinary trends, highlighting a $12 billion market that has been growing approximately 9% on average per year in recent years. Despite overall pet healthcare visits declining over the last three years, cats have enjoyed sustained visit and pricing growth, underscoring the compelling, scalable opportunity that, until now, has remained undiscovered within the broader long-term 'pet boom.'
"CATalyst Council is a 501(c)(3) nonprofit coalition of leaders in veterinary medicine, animal welfare, and the pet industry. It drives innovation in feline care by analyzing U.S. feline healthcare dynamics, owner behaviors, and veterinary trends."
The report confirms that, while the canine segment has dominated revenue in size, feline practice revenue has had higher average annual growth over the past 5 years. Beyond that, the current US total addressable feline veterinary market (TAM) remains at more than 2.5 times its current size, or an incremental $20 billion growth opportunity. This feline TAM simply assumes that cats reach the same rate of medicalization and level of care per visit as dogs presently enjoy.
' The growth we see in feline visits today, combined with favorable pet age demographics and an ongoing recovery in US real per capita income points to an exceptional growth opportunity arising in today's pet healthcare market,' said Jon Ayers, CATalyst Council board member and chair of its Market Insights Committee.
'Understanding feline species-specific stress responses and caregiver mindsets is critical,' said Kristin Wuhrman, Vice Chair of the CATalyst Council. 'By addressing costs, perceptions of value, and visit-related anxiety, adopting FelineVMA's Cat Friendly Practice care protocols, and educating caregivers on cat behavior, we can overcome key barriers and deepen the bond between cats, caregivers, and clinics, ultimately ensuring more cats receive the care they need.'
Volume II delivers the strategic playbook that practices, consolidators, industry suppliers, and investors need to build their investment plans:
Key Findings
$12 Billion Feline Veterinary Market with approximately 9% average annual growth: In 2024, feline practice revenue reached an estimated $11.7 billion, up from $7.6 billion in 2019, outpacing canine average annual growth (estimated at 7.5%, with 2024 US canine veterinary market of $48 billion).
Unmet Medicalization Gap: Only an estimated 30% of U.S. household-owned cats received a visit to a veterinary practice in 2024, compared to a corresponding estimated 65–70% for dogs.
Practice-Level Revenue Opportunity: Closing the care gap to match canine medicalization could expand the addressable market from $12 billion to $32 billion, adding an average of $680,000 (approximately 33%) to annual revenue to the average two-million-dollar U.S. veterinary practice location.
'Addressing the feline care gap should be a call to action for the entire animal health community,' adds Anne Ward, Chair of CATalyst Council. 'The feline veterinary segment has come of age with the opportunity for greater species-specific innovation by the industry and care profession.'
Recovery Forecast: CATalyst projects that pet age demographic headwinds faced in the last three years as a result of the aging and mortality of pets adopted during the depressed years of 2009-2011 following the 2008 great financial crisis, could turn to tailwinds as pets adopted from 2013 onwards reach their geriatric years, beginning in late 2025 or 2026. As the median lifespan of a cat is a little over 14 years, and correspondingly 13 years for a dog, these last few years of pet age are when visits are the highest after the first year of life. 'Pet demographics are hard trends and as inevitable as pet mortality and practice taxes,' said Jane Brunt DVM, proactive feline practice owner and CATalyst Council Executive Director.
This tailwind, combined with the potential for continued consumer inflation-adjusted income recovery, would accelerate feline visit growth and help reverse canine visit declines, starting in the next 6 to 18 months.
Looking Ahead: Data-Driven Validation
Building on these insights, CATalyst Council plans to field a 30,000 US-household 'State of the Cat' survey in late 2025. This extensive, statistically robust study will drill into regional, demographic, and behavioral nuances, enabling early adopters to pilot hyper-targeted programs and measure ROI against validated owner and feline needs. The 2025 CATalyst Feline Market Insights Reports, released quarterly and available exclusively to CATalyst Council sponsors, will inform each phase. CATalyst plans to share high-level conclusions throughout the year via press releases and LinkedIn, ensuring veterinary professionals, industry stakeholders, and decision-makers receive evidence-based updates.
To receive updates or inquire about the benefits of sponsorship, please visit catalystcouncil.org, and follow Catalyst Council on LinkedIn.
CATalyst Council is a national organization dedicated to accelerating innovation in feline care and enhancing quality of life for cats and their people. CATalyst's vision is to ensure all companion cats receive lifelong care by using evidence-based resources, embracing community-wide relationships for optimal health outcomes, and celebrating the human-feline bond.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Joyce University Expands Nursing Education to Residents in South Dakota, Oklahoma and Texas
Joyce University Expands Nursing Education to Residents in South Dakota, Oklahoma and Texas

Business Wire

time3 hours ago

  • Business Wire

Joyce University Expands Nursing Education to Residents in South Dakota, Oklahoma and Texas

SALT LAKE CITY--(BUSINESS WIRE)--Aspiring nurses in South Dakota, Oklahoma, and Texas can now prepare for RN licensure in as few as 20 months. Joyce University of Nursing and Health Sciences announced today that is expanding its innovative hybrid pre and post-licensure nursing programs into these states, reinforcing its commitment to providing accessible, high-quality nursing education nationwide. Joyce University continues to purposefully expand beyond its Utah origins, now offering programs across 16 states. This continued expansion reflects Joyce University's dedication to addressing the nationwide shortage of skilled nursing professionals through flexible, career-oriented educational pathways. 'Joyce University is driven by our shared vision to create educational opportunities that transform lives and positively impact communities,' said Josh Knotts, interim President and CEO. 'Expanding into South Dakota, Oklahoma, and Texas underscores our commitment to providing students nationwide with accessible, high quality nursing education that meets the evolving needs to today's healthcare environment.' With this expansion, students in South Dakota, Oklahoma, and Texas will have access to Joyce University's robust range of nursing programs, including the 20-month Associate of Science in Nursing (ASN), traditional 3 year Bachelor of Science in Nursing (BSN), and accelerated Bachelor of Science in Nursing (aBSN) for career changers. For those seeking career advancement, the university offers two online post-licensure programs: the 4 semester RN to BSN and the 3 semester MSN in Leadership. Joyce University's hybrid education model combines convenient online coursework with immersive, hands-on skills training at the Joyce Johnson Center of Simulation in Draper, Utah. Local clinical placements are conducted within South Dakota, Oklahoma, and Texas, allowing students to gain valuable experience within their communities. Enrollment for South Dakota, Oklahoma, and Texas students is now open, with the next cohort beginning September 2, 2025. For more information about Joyce University programs or employment opportunities, visit ABOUT JOYCE UNIVERSITY Founded in 1979, Joyce University of Nursing and Health Sciences' mission is to prepare students to serve as competent professionals, to advance their careers, and to pursue lifelong learning. Located in Draper, Utah, Joyce University is proud to have helped thousands of students across the US graduate and launch lasting healthcare careers. With a recent expansion of its pre-licensure programs to select regional locations, including Arizona, Colorado, Idaho, Kentucky, Michigan, Missouri, Nevada, New Mexico, Ohio, Oklahoma, Oregon, South Carolina, South Dakota, Texas, and Wisconsin, Joyce University's expansion enables aspiring nurses in these regions to access the same high-quality education and opportunities that have defined the institution for decades. Join them as they continue to shape the future of healthcare, one student at a time. Joyce University is institutionally accredited by the Northwest Commission on Colleges and Universities (NWCCU) and programmatically accredited by the Accreditation Commission for Education in Nursing (ACEN) for the Associate of Science in Nursing degree program and by the Commission on Collegiate Nursing Education (CCNE) for the Bachelor of Science in Nursing and Master of Science in Nursing degree programs.

Ash and Impilo Partner to Deliver Seamless At-Home Health Monitoring and Testing Nationwide
Ash and Impilo Partner to Deliver Seamless At-Home Health Monitoring and Testing Nationwide

Business Wire

time3 hours ago

  • Business Wire

Ash and Impilo Partner to Deliver Seamless At-Home Health Monitoring and Testing Nationwide

NEW YORK--(BUSINESS WIRE)--Ash, a leading at-home health testing platform, and Impilo, a leader in enabling at-home healthcare through its tech-enabled healthcare logistics and operations support, today announced a strategic partnership to expand access to comprehensive at-home health solutions across the U.S. By combining Ash's customizable health testing capabilities with Impilo's logistics and data platform, the collaboration creates a powerful, end-to-end offering for healthcare organizations, digital health companies, and health plans seeking to close care gaps and improve outcomes at scale. By combining our strengths, we are setting a new standard in the healthcare space, one that prioritizes access, impact, and real-world results. Under this partnership, Ash and Impilo clients will gain access to a one-stop solution that combines a comprehensive test menu spanning cancer screenings, HEDIS measures, chronic conditions, and infectious disease testing, paired with remote patient monitoring (RPM) devices including blood pressure monitors, EKGs, glucometers, scales, and wearables. Together, the companies help organizations close a wider range of care gaps, including key HEDIS measures such as blood pressure monitoring and diabetes control—all without requiring in-person visits. 'We're thrilled to announce our partnership with Ash, marking a major milestone for Impilo,' said Josh Stein, Founder & CEO of Impilo. 'This collaboration brings together two organizations deeply committed to closing gaps in care. By combining our strengths, we are setting a new standard in the healthcare space, one that prioritizes access, impact, and real-world results. We are bringing together our digital health fulfillment and platform capabilities with Ash's lab network to bring care to the next level.' The partnership streamlines the patient experience by consolidating devices and test kits into a single shipment, reducing friction and costs for both providers and patients. Early adopters plan to provide a comprehensive annual screening that includes a blood pressure cuff (supporting CBP and BPD HEDIS measures), lipids testing, and an A1c panel—all delivered together in one convenient white-labeled package. The result is a seamless, scalable approach to monitoring and health testing that enables proactive, data-driven care from home, requiring only one touchpoint for members. "We are proud to partner with Impilo to provide a solution that better closes care gaps and delivers improved outcomes for patients," said Kyle Waters, Co-Founder and Chief Product Officer of Ash. "Both Ash and Impilo share an unwavering commitment to patients and their health outcomes, and this philosophy is reflected throughout our products. Together, we're capturing high-value data where it doesn't currently exist, and filling in the blanks of an individual member's care journey to better drive care decisions and outcomes. Ultimately, this collaboration ensures patients are better understood and receive the comprehensive care they deserve." With rising demand for flexible, at-home health solutions, the Ash and Impilo partnership offers a new standard for how care can be delivered–cost-effectively, conveniently, and at scale. The partnership is now live and available to enterprise partners and healthcare organizations nationwide. About Ash Ash is a leading at-home health testing platform expanding care to reach those most in need. Working closely with our partners, we tailor end-to-end testing solutions that meet the unique needs of any health organization's population. Our strength comes from our unmatched understanding of people—whether that means learning the best ways to reach them or innovating a new way to keep them connected and cared for. We use our deep knowledge to develop field-tested best practices that engage hard to reach patients and members where they are. Because when people come first, better health outcomes are possible for all. Learn more at About Impilo Impilo's plug-and-play platform enables healthcare organizations to launch and scale connected care programs with ease. We streamline virtual care by offering integrated EHR capabilities, a device-agnostic infrastructure, and seamless procurement and ordering workflows for providers and payors alike. Impilo supports a wide range of healthcare partners, including payors, value based care entities, medical device companies, community health centers, and digital health organizations, to enable effective, scalable, and patient-centered care. Learn more at

Feinstein Institutes Awarded $2.3M, Joins Global Bipolar Disorder Research Network
Feinstein Institutes Awarded $2.3M, Joins Global Bipolar Disorder Research Network

Business Wire

time4 hours ago

  • Business Wire

Feinstein Institutes Awarded $2.3M, Joins Global Bipolar Disorder Research Network

MANHASSET, N.Y.--(BUSINESS WIRE)--To continue its groundbreaking bipolar disorder research, Northwell Health's The Feinstein Institutes for Medical Research has been awarded $2.3 million and joined the Breakthrough Discoveries for Thriving with Bipolar Disorder (BD²) Integrated Network, a national collaborative research and clinical care initiative aimed at transforming treatment and care for people living with bipolar disorder. Led by Caitlin Millett, PhD, assistant professor in the Feinstein Institutes' Institute of Behavioral Science, the site is located at Northwell Health's Zucker Hillside Hospital in Glen Oaks. The BD² Integrated Network's novel approach is a collaborative effort to drive scientific advancements by focusing on improving patient care in near-real time through cutting-edge biotechnology, big data analytics and an unprecedented data ecosystem to address bipolar disorder. The Feinstein Institutes joins nine other institutions, including the University of Cincinnati/Lindner Center of HOPE, University of California San Diego and The University of Texas at Austin as part of this national research collaboration. 'With this grant, we will contribute to a deeper understanding about bipolar disorder, with a focus on addressing the challenges of diagnosis and treatment.,' said Dr. Millett. 'We also hope to expand access to effective care for our patients.' Bipolar disorder is a complex and heterogeneous disorder, and more than 70% of people with bipolar disorder are misdiagnosed at least once. It takes seven years on average to diagnose bipolar disorder, and less than 50% of those who are diagnosed find an effective treatment. The research from each of these sites will involve both a large-scale longitudinal study and a learning health network model, allowing for continuous feedback between research findings and clinical practice. This approach aims to translate research discoveries into improved patient care more efficiently, and will focus on in-depth patient characterization, adherence to clinical guidelines and integration of research and clinical activities. 'Bipolar disorder is often misdiagnosed and effective treatments remain elusive for many living with it,' said Anil K. Malhotra, MD, co-director and professor of the Feinstein Institutes' Institute of Behavioral Science and vice chair for research with the Department of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. 'This funding allows us to contribute to a national effort to improve diagnosis, treatment, and ultimately, the lives of those affected by this complex disorder.' About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store